Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.42 |
| ▸ | MTOR | P42345 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261056 | 0.88 | PIK3CA (0.43) | KMT2AMAPK14MTORNPSR1PIK3CA | |
| SCHEMBL3190459 | 0.87 | HTT (0.40) | KMT2AMAPK14MTORNPSR1PIK3CA | |
| SCHEMBL13533581 | 0.81 | MTOR (0.42) | KMT2AMAPK14MTORCYP1A2CYP2C19 | |
| SCHEMBL3185281 | 0.77 | KMT2A (0.52) | ALDH1A1KMT2ACYP1A2CYP2C19NPSR1 | |
| SCHEMBL13533603 | 0.77 | MTOR (0.40) | KMT2AMAPK14MTORMEN1PIK3CA | |
| SCHEMBL3184059 | 0.76 | PIK3CA (0.41) | MAPK14MTORPIK3CA | |
| SCHEMBL20745726 | 0.75 | CRBN (0.53) | ALDH1A1KMT2AMTORCYP1A2PKM | |
| SCHEMBL6650527 | 0.73 | HCRTR1 (0.49) | ALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL6650987 | 0.72 | HCRTR1 (0.48) | ALDH1A1NPSR1 | |
| SCHEMBL1600136 | 0.72 | MAPK14 (0.61) | MAPK14MTORCYP1A2CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1970375-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | ALDH1A1 250/4885KMT2A 1304/4885MAPK14 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.